ArticleScientific reports2021

Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.

Masahito Masato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.